Offer for Cambridge Antibody

AstraZeneca PLC
07 June 2006

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OF SUCH JURISDICTION

                                                           FOR IMMEDIATE RELEASE

                                                                     7 June 2006



                             Recommended Cash Offer

                           by AstraZeneca UK Limited

                                      for

                    Cambridge Antibody Technology Group plc

The Board of AstraZeneca announces that AstraZeneca has fulfilled or waived all
of the conditions relating to competition authority consents detailed in
paragraphs 2.1, 2.2, 2.3, 3.1, 3.2 and 4 of the terms and conditions of its
offer for CAT contained in Appendix I, Part A of the Offer Document. On 31 May
2006, the Office of Fair Trading announced that it had decided that a relevant
merger situation, under the provisions of the Enterprise Act 2002, would not be
created by the acquisition of CAT by AstraZeneca. By a decision of 6 June 2006,
the German Federal Cartel Office cleared the proposed acquisition with regard to
German merger control laws.

Holders of CAT Securities are reminded that the first closing date of the Offer
is 21 June 2006, and acceptances of the Offer must accordingly be received by
3.00pm (London time), 10.00am (New York City time) on 21 June 2006.

Terms defined in the Offer Document dated 23 May 2006 have the same meanings in
this announcement.

Enquiries:

AstraZeneca
Media Enquiries:
Steve Brown (London)                             [phone]
Edel McCaffrey (London)                          [phone]
Staffan Ternby (Sweden)                          [phone]

Analyst/Investor Enquiries:
Jonathan Hunt (London)                           [phone]
Ed Seage (US)                                    [phone]
Jorgen Winroth (US)                              [phone]

Goldman Sachs International                      [phone]
Guy Slimmon
Mark Sorrell



This announcement is for informational purposes only and does not constitute an
offer to sell or an invitation to purchase any securities or the solicitation of
an offer to buy any securities, pursuant to the Offer or otherwise. This
announcement also does not constitute a Solicitation / Recommendation Statement
under the rules and regulations of the US Securities and Exchange Commission
(the 'SEC'). The Offer is being made solely by means of the Offer Document and
the Form of Acceptance accompanying the Offer Document, which contain the full
terms and conditions of the Offer, including details of how the Offer may be
accepted.  In the United States, AstraZeneca has filed a Tender Offer Statement
containing the Offer Document and other related documentation with the SEC on
Schedule TO and CAT has filed a Solicitation/Recommendation Statement with the
SEC on Schedule 14D-9.  Free copies of the Schedule TO, the Schedule 14D-9 and
the other related documents filed by AstraZeneca or CAT in connection with this
Offer are available on the SEC's website at http://www.sec.gov.  The Offer
Document and Acceptance Forms accompanying the Offer Document have been made
available to all CAT Shareholders at no charge to them.  CAT Shareholders are
advised to read the Offer Document and the accompanying Acceptance Forms as they
contain important information.  CAT Shareholders in the United States are also
advised to read the Tender Offer Statement and the Solicitation/Recommendation
Statement as they contain important information.

It should be noted that by virtue of the conflicting provisions of the City Code
and the Exchange Act, the Panel has agreed that the Acceptance Condition can be
structured so that the Offer cannot become or be declared unconditional as to
acceptances until such time as all other conditions of the Offer have been
satisfied, fulfilled or, to the extent permitted, waived.

Goldman Sachs International, which is authorised and regulated by the Financial
Services Authority, is acting exclusively for AstraZeneca and no one else in
connection with the Offer and will not be responsible to anyone other than
AstraZeneca for providing the protections afforded to clients of Goldman Sachs
International or for providing advice in relation to the Offer or any other
matters referred to in this announcement.

The availability of the Offer to CAT Shareholders who are not resident in and
citizens of the United Kingdom or the United States may be affected by the laws
of the relevant jurisdictions in which they are located or of which they are
citizens.  Such persons should inform themselves of, and observe, any applicable
legal or regulatory requirements of their jurisdictions.  Further details in
relation to overseas shareholders are contained in the Offer Document.

The Loan Notes which may be issued pursuant to the Loan Note Alternative have
not been, and will not be, listed on any stock exchange and have not been, and
will not be, registered under the Securities Act or under any relevant laws of
any state or other jurisdiction of the United States, nor have clearances been,
nor will they be, obtained from the securities commission or similar authority
of any province or territory of Canada and no prospectus has been, or will be,
filed, or registration made, under any securities law of any province or
territory of Canada, nor has a prospectus in relation to the Loan Notes been,
nor will one be, lodged with, or registered by, the Australian Securities and
Investments Commission, nor have any steps been taken, nor will any steps be
taken, to enable the Loan Notes to be offered in compliance with applicable
securities laws of Japan. Accordingly, unless an exemption under relevant
securities laws is available, the Loan Notes may not be offered, sold, re-sold
or delivered, directly or indirectly, in, into or from the United States or any
other Loan Note Restricted Jurisdiction in which an offer of Loan Notes would
constitute a violation of relevant laws or require registration of the Loan
Notes, or to or for the account or benefit of any US person or resident of any
other Loan Note Restricted Jurisdiction.

Unless otherwise determined by AstraZeneca and permitted by applicable law and
regulation, subject to certain exemptions, the Offer will not be capable of
acceptance from or within a Restricted Jurisdiction. Accordingly, copies of this
announcement must not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in, into or from a Restricted Jurisdiction and persons
receiving this announcement (including custodians, nominees and trustees) should
observe these restrictions and must not mail or otherwise distribute this
announcement in, into or from any such jurisdictions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange